Breast Cancer Clinical Trial

Safety of TofAcitinib in Routine Care Patients With Rheumatoid Arthritis (STAR-RA)-Cancer Endpoints

Summary

There are two main aims of this study.

First aim is to compare the risk of composite cancer outcomes, between patients treated with tofacitinib and patients treated with TNF inhibitors (TNFi) for rheumatoid arthritis (RA) among, 1) "real world evidence (RWE)" cohorts including routine care patient population from the US and, 2) "Randomized controlled trial (RCT) DUPLICATE" cohorts including routine care patient population who meet inclusion and exclusion criteria of the Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis ("ORAL Surveillance", NCT02092467) clinical trial.

Second aim is to examine the risk of common solid cancers (lung, colorectal, breast, prostate), hematological cancers, and non-melanoma skin cancer as separated endpoints when comparing tofacitinib with TNFi in patients with RA among, 1) "real world evidence (RWE)" cohort including routine care patient population from the US and, 2) "Randomized controlled trial (RCT) DUPLICATE" cohort including routine care patient population who meet inclusion and exclusion criteria of the Safety Study Of Tofacitinib Versus Tumor Necrosis Factor (TNF) Inhibitor In Subjects With Rheumatoid Arthritis ("ORAL Surveillance", NCT02092467) clinical trial.

View Eligibility Criteria

Eligibility Criteria

Criteria:

Please see https://www.bwhprime.org/resources.html for full code and algorithm definitions.

Eligible cohort entry dates:

For US MarketScan, 2012-2018
For Optum, 2012-2020
For Medicare Claims Database (Parts A, B and D), 2012-2017

Cohort entry date:

First TNFi or tofacitinib dispensation/administration date

Inclusion and Exclusion Criteria Common to RWE and RCT-duplicate Cohorts:

Inclusion Criteria

Patients treated with tofacitinib or TNF inhibitors in IBM MarketScan, Optum, and Medicare fee-for-service
A minimum of 365 days of continuous enrollment in health plan prior to (and including) the cohort entry date
Two diagnosis codes for RA in any setting in 365 days baseline period (diagnosis codes between 7 and 365 days apart)

Exclusion Criteria

Index drug in 365 days prior to cohort entry date (prevalent users)
Missing data on age or gender
Admission to nursing facility or hospice on or prior to cohort entry date (ever look-back)
Diagnosis of malignant cancer prior to cohort entry date (ever look-back period)
TNFi users with history of any Janus kinase (JAK) inhibitors (tofacitinib, upadacitinib, or baricitinib) (ever look-back period)
TNFi users initiating with more than one TNFi on same date
Tofacitinib users with a prescription of baricitinib, upadacitinib (ever look-back period)
Tofacitinib users initiating treatment on multiple JAK inhibitors on same day (tofacitinib and baricitinib, tofacitinib and upadacitinib)

Exclusion criteria specific to RWE cohorts:

Patients less than 18 years of age (MarketScan and Optum) and 65 years of age (Medicare) at cohort entry

Inclusion criteria specific to RCT-duplicate cohorts:

Patients with at least one methotrexate dispensation (six months look-back period)
Patients with at least one cardiovascular risk factor (including smoking, hypertension, dyslipidemia, diabetes mellitus, ischemic heart disease, family history of ischemic heart disease) (one-year look-back period)

Exclusion criteria specific to RCT-duplicate cohorts:

Patients less than 50 years of age (MarketScan and Optum) and 65 years
Patients recently hospitalized with infections (30-day look-back period)
Pregnant patients (one year look-back period)

Study is for people with:

Breast Cancer

Estimated Enrollment:

105711

Study ID:

NCT04798287

Recruitment Status:

Completed

Sponsor:

Brigham and Women's Hospital

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Brigham And Women's Hospital
Boston Massachusetts, 02120, United States

How clear is this clinincal trial information?

Study is for people with:

Breast Cancer

Estimated Enrollment:

105711

Study ID:

NCT04798287

Recruitment Status:

Completed

Sponsor:


Brigham and Women's Hospital

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider